BG62474B1 - Приложение на терпенови съединения за забавянеосвобождаването на арахидонова киселина и на възпалителнимедиатори - Google Patents

Приложение на терпенови съединения за забавянеосвобождаването на арахидонова киселина и на възпалителнимедиатори Download PDF

Info

Publication number: BG62474B1
Authority: BG; Bulgaria
Prior art keywords: day; cineol; mentan; therapy; use according
Prior art date: 1993-06-13

Application number

BG99499A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG99499A (bg

Inventor

Uwe R. Juergens

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-13

Filing date

1995-03-13

Publication date

1999-12-30

1993-06-13 Priority claimed from DE4319554A external-priority patent/DE4319554C2/de

1993-06-13 Priority claimed from DE19934319556 external-priority patent/DE4319556C2/de

1995-03-13 Application filed filed Critical

1995-12-29 Publication of BG99499A publication Critical patent/BG99499A/bg

1999-12-30 Publication of BG62474B1 publication Critical patent/BG62474B1/bg

Links

230000002757 inflammatory effect Effects 0.000 title description 15
-1 terpene compounds Chemical class 0.000 title description 6
235000007586 terpenes Nutrition 0.000 title description 5
208000006673 asthma Diseases 0.000 claims abstract description 13
238000011282 treatment Methods 0.000 claims abstract description 13
239000002775 capsule Substances 0.000 claims abstract description 8
238000002360 preparation method Methods 0.000 claims abstract description 3
239000003814 drug Substances 0.000 claims abstract 3
239000003978 infusion fluid Substances 0.000 claims abstract 2
WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims description 54
229960005233 cineole Drugs 0.000 claims description 36
229930007050 cineol Natural products 0.000 claims description 24
238000002560 therapeutic procedure Methods 0.000 claims description 21
230000000694 effects Effects 0.000 claims description 16
239000003246 corticosteroid Substances 0.000 claims description 13
229960001334 corticosteroids Drugs 0.000 claims description 12
208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 10
WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims description 2
238000011321 prophylaxis Methods 0.000 claims description 2
229940079593 drug Drugs 0.000 claims 2
210000004051 gastric juice Anatomy 0.000 claims 2
229960003444 immunosuppressant agent Drugs 0.000 claims 1
239000003018 immunosuppressive agent Substances 0.000 claims 1
239000007924 injection Substances 0.000 claims 1
238000002347 injection Methods 0.000 claims 1
210000003205 muscle Anatomy 0.000 claims 1
230000000241 respiratory effect Effects 0.000 claims 1
238000009097 single-agent therapy Methods 0.000 claims 1
239000000243 solution Substances 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 2
238000007918 intramuscular administration Methods 0.000 abstract description 2
230000001506 immunosuppresive effect Effects 0.000 abstract 1
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 16
RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 13
208000010668 atopic eczema Diseases 0.000 description 12
230000000172 allergic effect Effects 0.000 description 10
238000004519 manufacturing process Methods 0.000 description 10
230000002035 prolonged effect Effects 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
229940114079 arachidonic acid Drugs 0.000 description 7
235000021342 arachidonic acid Nutrition 0.000 description 7
150000003431 steroids Chemical class 0.000 description 7
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
229960004618 prednisone Drugs 0.000 description 6
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 6
239000000126 substance Substances 0.000 description 6
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 5
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 5
230000009471 action Effects 0.000 description 5
230000004199 lung function Effects 0.000 description 5
229940041616 menthol Drugs 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 4
102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 4
108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 4
208000027775 Bronchopulmonary disease Diseases 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
210000004969 inflammatory cell Anatomy 0.000 description 4
230000004060 metabolic process Effects 0.000 description 4
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 3
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000011340 continuous therapy Methods 0.000 description 3
229960004544 cortisone Drugs 0.000 description 3
230000021953 cytokinesis Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
230000009467 reduction Effects 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102000015439 Phospholipases Human genes 0.000 description 2
108010064785 Phospholipases Proteins 0.000 description 2
230000035508 accumulation Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
210000004789 organ system Anatomy 0.000 description 2
230000037361 pathway Effects 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
230000008569 process Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
RBNWAMSGVWEHFP-UHFFFAOYSA-N trans-p-Menthane-1,8-diol Chemical compound CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 description 2
DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
206010001889 Alveolitis Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
244000166124 Eucalyptus globulus Species 0.000 description 1
235000004692 Eucalyptus globulus Nutrition 0.000 description 1
PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
206010025327 Lymphopenia Diseases 0.000 description 1
240000005125 Myrtus communis Species 0.000 description 1
235000013418 Myrtus communis Nutrition 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010037596 Pyelonephritis Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000009858 acid secretion Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000003470 adrenal cortex hormone Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
230000009285 allergic inflammation Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
206010003230 arteritis Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229910000085 borane Inorganic materials 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
229940116229 borneol Drugs 0.000 description 1
208000030270 breast disease Diseases 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
208000003167 cholangitis Diseases 0.000 description 1
201000001352 cholecystitis Diseases 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
201000009151 chronic rhinitis Diseases 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010411 cooking Methods 0.000 description 1
RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
239000000284 extract Substances 0.000 description 1
201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
229960000676 flunisolide Drugs 0.000 description 1
229960003973 fluocortolone Drugs 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
230000007774 longterm Effects 0.000 description 1
231100001023 lymphopenia Toxicity 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
235000012245 magnesium oxide Nutrition 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
231100000989 no adverse effect Toxicity 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
208000001297 phlebitis Diseases 0.000 description 1
239000004033 plastic Substances 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000003505 terpenes Chemical group 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Steroid Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Pyrane Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BG99499A 1993-06-13 1995-03-13 Приложение на терпенови съединения за забавянеосвобождаването на арахидонова киселина и на възпалителнимедиатори BG62474B1 (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE4319554A DE4319554C2 (de)	1993-06-13	1993-06-13	Verwendung von Menthol zur peroralen entzündungshemmenden Behandlung von Asthma bronchiale
DE19934319556 DE4319556C2 (de)	1993-06-13	1993-06-13	Verwendung von 1,8-Cineol zur entzündungshemmenden Behandlung von steroidpflichtigem Asthma bronchiale
PCT/EP1994/001900 WO1994028895A2 (de)	1993-06-13	1994-06-11	Verwendung von terpenverbindungen zur verminderten freisetzung von arachidonsäure und entzündungsmediatoren

Publications (2)

Publication Number	Publication Date
BG99499A BG99499A (bg)	1995-12-29
BG62474B1 true BG62474B1 (bg)	1999-12-30

Family

ID=25926728

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG99499A BG62474B1 (bg)	1993-06-13	1995-03-13	Приложение на терпенови съединения за забавянеосвобождаването на арахидонова киселина и на възпалителнимедиатори

Country Status (19)

Country	Link
US (1)	US5889049A (sk)
EP (1)	EP0654994B1 (sk)
JP (1)	JPH08500612A (sk)
AT (1)	ATE173622T1 (sk)
AU (1)	AU680663B2 (sk)
BG (1)	BG62474B1 (sk)
BR (1)	BR9405404A (sk)
CA (1)	CA2140660A1 (sk)
CZ (1)	CZ285025B6 (sk)
DE (1)	DE59407336D1 (sk)
DK (1)	DK0654994T3 (sk)
ES (1)	ES2126123T3 (sk)
HU (1)	HUT69684A (sk)
NO (1)	NO313814B1 (sk)
PL (1)	PL308539A1 (sk)
RO (1)	RO111989B1 (sk)
RU (1)	RU2161482C2 (sk)
SK (1)	SK282308B6 (sk)
WO (1)	WO1994028895A2 (sk)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2693654B1 (fr) *	1992-07-20	1994-08-26	Oreal	Médicament, notamment immunomodulateur, contenant des enveloppes ou fractions d'enveloppes de bactéries filamenteuses non photosynthétiques et non fructifiantes, et sa préparation.
SE9604751D0 (sv) *	1996-12-20	1996-12-20	Astra Ab	New therapy
GB2329583A (en) *	1997-09-25	1999-03-31	Marilyn Rydstrom	Use of tea-tree oil for prophylaxis against cystitis
CN1125651C (zh)	1998-04-16	2003-10-29	欧维塔有限公司	新颖的、含有存在于大高良姜中的芳族化合物与萜类化合物的协同组合物
US6420435B1 (en)	1999-11-01	2002-07-16	Joe S. Wilkins, Jr.	Method for treating gastrointestinal disorders
US6733794B1 (en) *	1999-12-17	2004-05-11	Edward L. Ingram	Topical composition for antiseptic and analgesic purposes
US7041706B2 (en) *	2002-04-19	2006-05-09	Wilkins Jr Joe S	Method for treating crohn's disease
RU2210357C1 (ru) *	2002-04-26	2003-08-20	Леонова Наталия Сергеевна	Ароматический лечебно-профилактический состав доктора леоновой н.с.
US7790762B2 (en) *	2002-10-31	2010-09-07	National Jewish Health	Compounds and methods for thiol-containing compound efflux and cancer treatment
US20080221029A1 (en) *	2002-10-31	2008-09-11	Regents Of The University Of Colorado	Methods for treatment of thiol-containing compound deficient conditions
US20040087527A1 (en) *	2002-10-31	2004-05-06	Day Brian J.	Methods for treatment of thiol-containing compound deficient conditions
US20110257138A1 (en)	2008-09-04	2011-10-20	Harold Greve	Monoterpenes for treating respiratory tract diseases, in particular bronchopulmonary diseases
DE202010007074U1 (de)	2010-05-12	2011-08-12	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Neue Darreichungsformen für Cineol
DE102010022174A1 (de)	2010-05-12	2011-11-17	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Neue Darreichungsformen für Cineol
DK2627673T3 (da) *	2010-10-15	2017-11-06	Medimmune Ltd	Terapier til forbedring af lungefunktionen
PL2672981T3 (pl) *	2011-02-11	2018-09-28	Zx Pharma, Llc	Wielocząstkowe preparaty l-mentolu i powiązane sposoby
DE102012001731A1 (de) *	2012-01-20	2013-07-25	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Systemische Darreichungsformen mit kontrollierter Freisetzung und verbesserter Stabilität
JP2012131823A (ja) *	2012-03-12	2012-07-12	Lotte Co Ltd	線毛運動活性化剤及びそれを含む飲食品

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4103019A (en) *	1975-10-07	1978-07-25	Laboratorios Landerlan, S. A.	Triterpene derivatives
ES537162A0 (es) *	1983-10-31	1985-12-01	Merck Frosst Canada Inc	Una composicion farmaceutica
JP2524709B2 (ja) *	1985-09-26	1996-08-14	塩野義製薬株式会社	鎮痛消炎作用増強剤
US5120538A (en) *	1990-02-05	1992-06-09	Pt Darya-Varia Laboratoria	Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
US5616458A (en) *	1990-03-14	1997-04-01	Board Of Regents, University Of Tx System	Tripterygium wilfordii hook F extracts and components, and uses thereof
WO1991013627A1 (en) *	1990-03-14	1991-09-19	The Board Of Regents, The University Of Texas System	Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
US5580562A (en) *	1990-03-14	1996-12-03	Board Of Regents The University Of Texas System	Preparations and uses thereof for immunosuppression
JPH0426619A (ja) *	1990-05-18	1992-01-29	Lotte Co Ltd	抗アレルギー剤および抗アレルギー剤を含有する食品添加物
AU1783092A (en) *	1991-04-08	1992-11-02	United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The	Inhibitors of protein kinase c function
US5322689A (en) *	1992-03-10	1994-06-21	The Procter & Gamble Company	Topical aromatic releasing compositions
DE4211745A1 (de) *	1992-04-03	1993-10-07	Boerner Gmbh	Verwendung von Propolis und/oder seinen Fraktionen
US5338758A (en) *	1992-04-03	1994-08-16	Schering Corporation	Bicyclic diterpene PAF antagonist compounds
US5527890A (en) *	1993-04-16	1996-06-18	Glycomed Incorporated	Derivatives of triterpenoid acids and uses thereof
US5464754A (en) *	1993-08-17	1995-11-07	The Regents Of The University Of California	Assay and substrate for arachidonoyl-specific phospholipase A2
US5665386A (en) *	1995-06-07	1997-09-09	Avmax, Inc.	Use of essential oils to increase bioavailability of oral pharmaceutical compounds

1993
- 1993-06-11 CA CA002140660A patent/CA2140660A1/en not_active Abandoned
1994
- 1994-06-11 AT AT94918864T patent/ATE173622T1/de active
- 1994-06-11 CZ CZ95370A patent/CZ285025B6/cs not_active IP Right Cessation
- 1994-06-11 AU AU70003/94A patent/AU680663B2/en not_active Ceased
- 1994-06-11 RU RU95109447/14A patent/RU2161482C2/ru active
- 1994-06-11 HU HU9500714A patent/HUT69684A/hu unknown
- 1994-06-11 PL PL94308539A patent/PL308539A1/xx unknown
- 1994-06-11 DE DE59407336T patent/DE59407336D1/de not_active Expired - Lifetime
- 1994-06-11 EP EP94918864A patent/EP0654994B1/de not_active Expired - Lifetime
- 1994-06-11 JP JP7501336A patent/JPH08500612A/ja active Pending
- 1994-06-11 RO RO95-00226A patent/RO111989B1/ro unknown
- 1994-06-11 DK DK94918864T patent/DK0654994T3/da active
- 1994-06-11 SK SK303-95A patent/SK282308B6/sk not_active IP Right Cessation
- 1994-06-11 BR BR9405404A patent/BR9405404A/pt not_active Application Discontinuation
- 1994-06-11 ES ES94918864T patent/ES2126123T3/es not_active Expired - Lifetime
- 1994-06-11 WO PCT/EP1994/001900 patent/WO1994028895A2/de not_active Ceased
- 1994-06-11 US US08/373,294 patent/US5889049A/en not_active Expired - Fee Related
1995
- 1995-02-10 NO NO19950518A patent/NO313814B1/no not_active IP Right Cessation
- 1995-03-13 BG BG99499A patent/BG62474B1/bg unknown

Also Published As

Publication number	Publication date
NO950518D0 (no)	1995-02-10
WO1994028895A2 (de)	1994-12-22
DE59407336D1 (de)	1999-01-07
US5889049A (en)	1999-03-30
RO111989B1 (ro)	1997-04-30
NO313814B1 (no)	2002-12-09
BG99499A (bg)	1995-12-29
EP0654994A1 (de)	1995-05-31
BR9405404A (pt)	1999-05-25
WO1994028895A3 (de)	1995-04-06
SK282308B6 (sk)	2002-01-07
NO950518L (no)	1995-02-10
CZ285025B6 (cs)	1999-05-12
RU2161482C2 (ru)	2001-01-10
ATE173622T1 (de)	1998-12-15
SK30395A3 (en)	1995-11-08
DK0654994T3 (da)	1999-08-09
ES2126123T3 (es)	1999-03-16
AU7000394A (en)	1995-01-03
HU9500714D0 (en)	1995-04-28
HUT69684A (en)	1995-09-28
EP0654994B1 (de)	1998-11-25
CA2140660A1 (en)	1994-12-22
JPH08500612A (ja)	1996-01-23
PL308539A1 (en)	1995-08-21
CZ37095A3 (en)	1995-11-15
AU680663B2 (en)	1997-08-07

Publication	Publication Date	Title
BG62474B1 (bg)	1999-12-30	Приложение на терпенови съединения за забавянеосвобождаването на арахидонова киселина и на възпалителнимедиатори
EP1024146B1 (en)	2009-12-30	Use of a steroid saponin for the treatment of dementia
Juergens et al.	1998	Inhibition of cytokine production and arachidonic acid metabolism by eucalyptol (1.8-cineole) in human blood monocytes in vitro
Kirsch et al.	1988	Effect of eicosapentaenoic acid in asthma
EP1696932B1 (en)	2009-09-02	Use of treprostinil to improve kidney functions
Thorn et al.	1957	Some effects of adrenal cortical steroids on intermediary metabolism
US5260335A (en)	1993-11-09	Pharmaceutical preparations for the treatment of inflammatory diseases
JP2011516478A (ja)	2011-05-26	免疫療法のための組成物および方法
EP2723344B1 (de)	2015-10-07	Monoterpenhaltiges kombinationstherapeutikum
Jackson et al.	1981	6-Keto-prostaglandin E1 is more potent than prostaglandin I2 as a renal vasodilator and renin secretagogue.
Freesemann et al.	1995	Treatment of porphyria cutanea tarda by the effect of chloroquine on the liver
US10124012B2 (en)	2018-11-13	Method for treatment of hyperglycemia and hyperlipidemia
Krishnaswamy et al.	1970	Mental changes and platelet serotonin in pellagrins
CN101070338A (zh)	2007-11-14	丹参酮ⅱa磺酸钾用于制备预防和治疗心肌缺血缺氧、脑缺血缺氧的药物
US8114906B2 (en)	2012-02-14	Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease
US6498145B1 (en)	2002-12-24	Use of purified SDG as a hypotensive (vasodilator) agent
Garrod	1958	The pharmacology of cortisone, cortisol (hydrocortisone) and their new analogues
Streeten et al.	1959	The hepatic metabolism of adrenocortical steroids and some clinical implications thereof
Mantero	1981	4 Exogenous mineralocorticoid-like disorders
Akkuş et al.	2020	Cushing syndrome induced by long term use of corticosteroids in the management of atopic dermatitis
CN119656178A (zh)	2025-03-21	积雪草酸在制备抗动脉粥样硬化药物中的应用
Ferri et al.	1987	Plasma exchange in the treatment of progressive systemic sclerosis
KR100245670B1 (ko)	2000-08-01	종양괴사인자 매개성 피부질환 치료제 조성물
Jaimovich et al.	1992	Management of reactive airway disease
CN120938984A (zh)	2025-11-14	萝卜硫素在制备治疗血管内皮受损药物中的应用